- Home
- WPP vs MDGL Comparison
WPP vs MDGL Comparison
Compare WPP & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WPP
- MDGL
- Stock Information
- Founded
- WPP 1985
- MDGL 2011
- Country
- WPP United Kingdom
- MDGL United States
- Employees
- WPP N/A
- MDGL N/A
- Industry
- WPP Advertising
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- WPP Consumer Discretionary
- MDGL Health Care
- Exchange
- WPP Nasdaq
- MDGL Nasdaq
- Market Cap
- WPP 7.6B
- MDGL 6.8B
- IPO Year
- WPP N/A
- MDGL N/A
- Fundamental
- Price
- WPP $38.88
- MDGL $299.57
- Analyst Decision
- WPP Hold
- MDGL Strong Buy
- Analyst Count
- WPP 1
- MDGL 10
- Target Price
- WPP N/A
- MDGL $420.63
- AVG Volume (30 Days)
- WPP 317.1K
- MDGL 383.5K
- Earning Date
- WPP 02-27-2025
- MDGL 05-01-2025
- Dividend Yield
- WPP 3.06%
- MDGL N/A
- EPS Growth
- WPP 389.11
- MDGL N/A
- EPS
- WPP 0.62
- MDGL N/A
- Revenue
- WPP $18,454,623,978.00
- MDGL $317,383,000.00
- Revenue This Year
- WPP N/A
- MDGL $230.69
- Revenue Next Year
- WPP $1.94
- MDGL $74.76
- P/E Ratio
- WPP $12.23
- MDGL N/A
- Revenue Growth
- WPP N/A
- MDGL N/A
- 52 Week Low
- WPP $31.52
- MDGL $200.08
- 52 Week High
- WPP $57.37
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- WPP 56.22
- MDGL 41.29
- Support Level
- WPP $38.46
- MDGL $287.46
- Resistance Level
- WPP $39.46
- MDGL $349.00
- Average True Range (ATR)
- WPP 0.56
- MDGL 17.83
- MACD
- WPP 0.42
- MDGL -1.99
- Stochastic Oscillator
- WPP 87.45
- MDGL 32.10
About WPP WPP plc
Headquartered in the United Kingdom, WPP is one of the world's largest ad holding companies based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.